VA
ACRS icon

Verdad Advisers’s Aclaris Therapeutics ACRS Stock Holding History

Verdad Advisers’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$739K Buy
+197,042
New +$665K 0.83% 35

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verdad Advisers's ACRS Position: Q1 2026 in Review

Verdad Advisers opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 197,042 shares worth $739K. The stake represents 0.83% of the portfolio and ranks #35 among its holdings.

136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Verdad Advisers held 197,042 shares of Aclaris Therapeutics worth $739K as of Q1 2026.
  • Aclaris Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Aclaris Therapeutics made up 0.83% of Verdad Advisers's portfolio in Q1 2026, its #35 holding.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.